RSS Parrot

Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century

https://pubmed.ncbi.nlm.nih.gov/41949336/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260408152908&v=2.19.0.post6+133c1fe

Published: April 8, 2026 10:00

CONCLUSION: The evidence from clinical trials was quickly incorporated into clinical practice, leading to higher pCR rates and benefits for patients. In the next step, the implementation of immune checkpoint inhibitors in real-world practice will be…

An Exploratory Study on Prognostic Prediction and Interpretability Analysis in Early-stage Triple-negative Breast Cancer Using Pathological Images

https://pubmed.ncbi.nlm.nih.gov/41944767/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260407134537&v=2.19.0.post6+133c1fe

Published: April 7, 2026 10:00

CONCLUSION: This study demonstrates that deep learning can enable accurate prognostic prediction in early-stage TNBC, with interpretable image features that reflect the tumor immune microenvironment and gene expression profiles.

Integrative QSP Modeling of Cancer Stem Cells in Triple-Negative Breast Cancer: Impacts on Tumor Immunity and Response to Immune Checkpoint Inhibitors

https://pubmed.ncbi.nlm.nih.gov/41943505/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260407134537&v=2.19.0.post6+133c1fe

Published: April 7, 2026 10:00

Cancer stem cells (CSCs) contribute to an immunosuppressive microenvironment through complex mechanisms and tumor-immune interactions. However, the key determinants of CSC characteristics in driving tumor progression, immune suppression, and response to…

An Experimental Study into the Photodynamic/Sonodynamic Therapy of Triple-Negative Breast Cancer Mediated by the Novel Nano-Photonic Sensitizer NBDPBr Nanoparticles

https://pubmed.ncbi.nlm.nih.gov/41939215/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260406192220&v=2.19.0.post6+133c1fe

Published: April 6, 2026 10:00

CONCLUSION: NBDPBr NPs mediate potent synergistic PDT/SDT against TNBC, supported by a dual-modal URM/PAI imaging platform for treatment monitoring. This study presents a promising theranostic strategy with high translational potential for TNBC management.

Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC

https://pubmed.ncbi.nlm.nih.gov/41931605/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260403225108&v=2.19.0.post6+133c1fe

Published: April 3, 2026 10:00

Systemic neoadjuvant chemotherapy, often combined with immunotherapy, is the standard of care for early-stage, non-breast cancer susceptibility gene (BRCA)-mutant triple negative breast cancer (TNBC). However, up to 70% of patients retain residual disease…

Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer

https://pubmed.ncbi.nlm.nih.gov/41925872/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260402174755&v=2.19.0.post6+133c1fe

Published: April 2, 2026 10:00

Triple-negative breast cancer (TNBC) lacks effective targeted treatments, rendering γδ T cell immunotherapy a promising therapeutic strategy. However, the function of these immune cells is often limited by exhaustion and immunosuppression. This study…

WFDC21P is essential for G3BP1-mediated RIG-I activation and antitumor immunity in triple-negative breast cancer

https://pubmed.ncbi.nlm.nih.gov/41915747/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260331210708&v=2.19.0.post6+133c1fe

Published: March 31, 2026 10:00

Deciphering the mechanisms underlying antitumor immunity is critical for improving cancer immunotherapy efficacy. Here, we identify WFDC21P (lnc-DC) as a positive regulator of antitumor immunity through promoting the activation of the RNA-sensing retinoic…

Network-based exploration of 4-(phenylsulfonyl)morpholine molecules for metastatic triple-negative breast cancer suppression

https://pubmed.ncbi.nlm.nih.gov/41915639/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260331210708&v=2.19.0.post6+133c1fe

Published: March 31, 2026 10:00

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer, with limited treatment options due to the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2)…

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy

https://pubmed.ncbi.nlm.nih.gov/41910838/?utm_source=RSS-Parrot-Bot&utm_medium=rss&utm_campaign=None&utm_content=1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2&fc=None&ff=20260330232642&v=2.19.0.post6+133c1fe

Published: March 30, 2026 10:00

CONCLUSIONS: In this real-world cohort, achieving pCR after carboplatin-containing NACT was the strongest determinant of favorable prognosis. Adjuvant capecitabine was not associated with statistically significant improvement in survival outcomes. The role…